APA (7th ed.) Citation

John Nemunaitis, Laura Stanbery, Adam Walter, Adam Walter, Rodney Rocconi, Philip Stephens, & Philip Stephens. (2023). Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

John Nemunaitis, Laura Stanbery, Adam Walter, Adam Walter, Rodney Rocconi, Philip Stephens, and Philip Stephens. Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer. Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

John Nemunaitis, et al. Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer. Frontiers Media S.A., 2023.